Next Article in Journal
Antimicrobial Effectiveness of Calcium Silicate Sealers against a Nutrient-Stressed Multispecies Biofilm
Previous Article in Journal
Special Issue “COVID-19: Diagnostic Imaging and Beyond”
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 9
Issue 9
10.3390/jcm9092723
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease

by
Swetha R. Kanduri
1,
Karthik Kovvuru
1,
Panupong Hansrivijit
2,
Charat Thongprayoon
3,
Saraschandra Vallabhajosyula
4,
Aleksandra I. Pivovarova
5,
Api Chewcharat
3,
Vishnu Garla
6,
Juan Medaura
5 and
Wisit Cheungpasitporn
3,5,*
1
Department of Nephrology, Ochsner Medical Center, New Orleans, LA 70121, USA
2
Department of Internal Medicine, University of Pittsburgh Medical Center Pinnacle, Harrisburg, PA 17105, USA
3
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA
4
Section of Interventional Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
5
Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39156, USA
6
Department of Internal Medicine and Mississippi Center for Clinical and Translational Research, University of Mississippi Medical Center, Jackson, MS 39156, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(9), 2723; https://doi.org/10.3390/jcm9092723
Submission received: 20 August 2020 / Accepted: 20 August 2020 / Published: 24 August 2020
(This article belongs to the Section Nephrology & Urology)
Browse Figure
Versions Notes

Abstract

:
Globally, diabetes mellitus is a leading cause of kidney disease, with a critical percent of patients approaching end-stage kidney disease. In the current era, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as phenomenal agents in halting the progression of kidney disease. Positive effects of SGLT2i are centered on multiple mechanisms, including glycosuric effects, tubule—glomerular feedback, antioxidant, anti-fibrotic, natriuretic, and reduction in cortical hypoxia, alteration in energy metabolism. Concurrently, multiple kidney and cardiovascular outcome studies have reported remarkable advantages of SGLT2i including mortality benefits. Additionally, the superiority of combination therapies (SGLT2I along with metformin/DDP-4 Inhibitors) in treatment-naïve diabetic patients is further looked into with potential signal towards glycemic and blood pressure control. Reported promising results initiate a gateway for future research targeting kidney outcomes with combination therapies as an initial approach. In the current paper, we summarize leading cardiovascular and kidney outcome trials in patients with type 2 diabetes, the role of SGLT2i in non-diabetic proteinuric kidney disease, and the potential mechanisms of action of SGLT2i with special focus on combination therapy as an initial therapeutic approach in treatment-naïve diabetic patients.

1. Introduction

Diabetes mellitus and associated conditions including hypertension, obesity, and atherosclerosis significantly contribute to progression of chronic kidney disease (CKD), cardiovascular health, and overall mortality [1,2,3,4,5,6,7,8]. Diabetes is an evolving global pandemic with diabetic kidney disease accounting for 44.5% of new end-stage kidney disease (ESKD) cases [1,2]. Two defined pathways that have been proposed to describe the evolution of diabetic kidney disease are hemodynamic and non-hemodynamic [9]. Although not fully understood, the role of hyperglycemia in pathophysiology of diabetic complications has been attributed to an increase in intra-glomerular pressure, elevation of single nephron glomerular filtration rate (GFR), and podocyte damage further perpetuating renal dysfunction [10]. Other contributory mechanisms include neurohumoral activation and cytokine release, along with proinflammatory pathway activation, potentiating tubulointerstitial inflammation and fibrosis [11,12].
Over the past 20 years, angiotensin receptor blockers (ACE) have been used in attenuating neuro-humoral activation and reducing intra-glomerular hypertension. ACE inhibitors reduce doubling of serum creatinine and progression to ESKD by about 20% [13,14]. Even though renin-angiotensin aldosterone system (RAAS) blockade helps reduce glomerular hypertension, they were unsuccessful in normalizing hyperfiltration, reduction of cardiovascular disease, and mortality [15]. With the introduction of sodium-glucose co-transporter 2 inhibitors (SGLT2i) there has been a fundamental change in treatment paradigm of patients with CKD secondary to diabetic nephropathy [16,17,18,19,20].
SGLT2i have been increasingly recognized for their remarkable renoprotective and cardioprotective benefits [21,22,23,24]. Not surprisingly, because of their well-established benefits, SGLT2i has reshaped the treatment algorithm of type 2 diabetes mellitus. After the initial discovery of phlorizin, a non-selective SGLTi, multiple other formulations have since emerged [25,26]. Approximately 80–90% of filtered glucose is actively reabsorbed via SGLT2, located at the S1 segment of the proximal tubule, at a concentration of 1:1 with sodium. Additionally, SGLT1, located at S2/S3 segment of the proximal tubule, utilizes more energy and helps to reabsorb 10–20% of glucose in association with two sodium molecules [27,28]. Because of their glycosuric properties, SGLT2i contributes to weight loss of approximately 2 to 3 kg [29,30]. Subsequently, 3 to 5 mmHg systolic and 1 to 2 mmHg diastolic blood pressure lowering effects are being encountered [29,30,31]. The above-mentioned anti-hypertensive benefits of SGLT2i are implicated across all ranges of estimated GFR (eGFR) even among patients with stage 4 CKD [31]. Multiple randomized controlled studies have reported substantial benefits of combination therapy with SGLT2i and metformin as initial approach in patients with type 2 diabetes [32,33,34]. With that being said, American Diabetes Association 2020 guidelines recommend prescribing an SGLT2i following initial trial of lifestyle modifications and metformin in patients with CKD, cardiovascular disease, and heart failure [35].
The seminal study by Milder et al. reviewed efficacy and safety of a combination approach of SGLT2i and metformin in treatment-naïve type 2 diabetic patients [36]. Four randomized controlled studies with a total of 3749 patients were included. The outcomes of the study were substantially in favor of combination therapy, showing significant reduction in hemoglobin A1c compared with monotherapy after 24–26 weeks of treatment. High dose SGLT2i/metformin combination therapy dapagliflozin 10 mg or canagliflozin 300 mg, as compared to low dose combination therapy dapagliflozin 5 mg or canagliflozin 100 mg, appears to cause modest weight reduction without glycemic benefits. Additionally, data revealed that combination therapy provided statistically significant reduction in systolic and diastolic blood pressure as compared to metformin alone. However, no difference in blood pressure was noted when combination therapy is compared to SGLT2i alone. Safety profile was in favor of combination therapy, with a mildly increased risk of diarrhea with combination therapy. Although this systematic review reported particular benefits of combination therapy as initial strategy, it did not address the role of combination therapy in lowering proteinuria or effects on rise of serum creatinine.
Significant benefits of SGLT2i in type 2 diabetic patients outweigh minor side effect profile mentioned in the literature. Furthermore, appropriate preventive steps can be undertaken to help mitigate potential adverse effects. For example, SGLT2i has been associated with increased risk of mycotic genital infections, necessitating frequent monitoring and good hygiene. It has been proposed that prophylactic antifungals could be considered in patients with high risk of fungal infections. Additionally, SGLT2i has demonstrated significant natriuretic effects, which necessitates holding the doses in patients with nausea and vomiting or other conditions that would make them more prone to dehydration. Avoiding SGLT2i with early signs of DKA is also recommended due to concerns of worsening acidosis. Careful consideration should be given to the risk of urinary tract infections associated with SGLT2i. Lastly, patients with open foot wounds or skin ulcers should also be cautious due to some existing reports of lower limb amputations linked to SGLT2i [37,38,39,40].

2. Clinical Trials

2.1. Major Cardiovascular Outcomes Trials

Based on recognized health benefits of SGLT2i, multicenter, randomized controlled studies were conducted evaluating renal and cardiovascular outcomes. As a pioneer agent, empagliflozin was compared to placebo in patients with type 2 diabetes mellitus at high risk of cardiovascular events [41]. Among 7020 diabetic patients included in the study, there were 1819 CKD patients with GFR > 30 mL/min [21]. Interestingly, a 14% reduction in risk of death, including from cardiovascular causes, non-fatal myocardial infarctions (MI), and non-fatal stroke, was reported. Wanner et al. analyzed long term renal outcomes from participants of EMPA REG OUTCOME study. The results of the study showed a 39% relative risk reduction in progression of albuminuria, a 44% relative risk reduction in serum creatinine doubling, and a 55% relative risk reduction in initiation of renal-replacement therapy (RRT) [41]. Subsequently, CANVAS trial compared efficacy and safety of canagliflozin in patients with type 2 diabetes compared to placebo [42]. This study included 10,000 participants reporting cardiovascular outcomes. Around 2039 patients had kidney disease with a mean eGFR of 76.5 mL/min. Similar results were encountered with around a 14% decrease in composite risk of death from non-fatal MI, non-fatal stroke, and cardiovascular causes. While the primary goal of the trial was to evaluate cardiovascular outcomes, significant renoprotective effect was also observed. Approximately a 40% reduction in death from kidney causes, decline in GFR, and need for RRT were reported. Another multicenter placebo-controlled trial, DECLARE—TIMI, compared dapagliflozin to placebo in patients with type 2 diabetes evaluating the cardiovascular safety, confirmed sustained benefits of SGLT2i [22]. Moreover, this trial reported remarkable kidney-specific benefits with about 40% decrease in rate of GFR decline, progression to ESKD and death from kidney causes.

2.2. Major Kidney-Specific Outcome Trials

Some of the renal specific outcomes were studied in multicentric, double-blind, randomized trial, CREDENCE. This study looked at the effects of canagliflozin in patients with type 2 diabetes and albuminuric CKD [43]. This has been one of the first studies which specifically included albuminuric CKD patients. Included patients had GFR of 30–90 mL per minute per 1.73 m2 of body-surface area and albuminuria of greater than 300 mg/g. Due to the apparent benefit of the drug observed in the study, CREDENCE trial was stopped earlier. Around 34% relative risk reduction in doubling of serum creatinine, progression to ESKD, and death from renal causes have been reported. Besides renal specific advantage, cardiovascular benefits were also observed.
Recently, another multicentric, double-blind, randomized trial, DAPA-CKD, compared dapagliflozin to placebo. This trial specifically included late-stage CKD patients with GFR above 25 and below 75 mL/min, albuminuric patients with urine albumin-to-creatinine ratio of equal or above 200 and equal or below 5000 mg/g in patients with or without diabetes. Similar to CREDENCE, this trial was also stopped early given demonstrated superior efficacy of dapagliflozin. Primary endpoint was defined as a composite of an eGFR decline of at least 50%, onset of ESKD, and death from cardiovascular or renal cause in patients with CKD regardless of presence of diabetes.
Lastly, there is currently an ongoing randomized double-blind placebo-controlled EMPA-KIDNEY trial, which was designed to evaluate safety and efficacy of empagliflozin in 5000 CKD patients with albuminuria of above 200 mg/g and eGFR 20–45 mL/min or 45–90 mL/min/1.73 m2 (Table 1).

2.3. Role of SGLT2 in Non-Diabetic CKD Patients

Several pre-clinical studies/animal models have been published evaluating the role of SGLT2i in non-diabetic CKD. However, well-defined conclusion could not be established due to conflicting results [55,56,57]. As far as clinical studies, at this point it is unclear if there is a sustained clinical benefit in cardiovascular or renal outcomes in non-diabetic patients. A pilot study by Rajasekeran et al., which included ten patients with FSGS, evaluated the effects of 8 weeks of dapagliflozin on GFR and proteinuria [58]. Dapagliflozin failed to demonstrate additional effects on body weight, proteinuria or measured GFR. A Phase 2 randomized, double-blind study by Bays et al. enrolled 376 overweight and obese non-diabetic patients to evaluate the effects of canagliflozin on body weight [59]. Even though there was significant reduction in body weight, no effect on proteinuria was observed.
Dapagliflozin was studied in a randomized, double-blind, placebo-controlled study, DIAMOND, which included proteinuric, non-diabetic CKD patients with eGFR of at least 25 mL/min/1.73 m2 [50]. A total of 53 patients included in the study had proteinuria ranging from 500 to 3500 mg per 24 h. A reduction in body weight by 1.5 kilos was observed in dapagliflozin group compared to placebo during a 6-week period, yet neither significant reduction in systolic or diastolic blood pressure nor reduction in proteinuria were detected. In addition, an acute and reversible decline in measured GFR was noted in dapagliflozin group. Long-term clinical studies in evaluating the potential benefit of SGLT2i in non-diabetic CKD patients are required before reaching a meaningful conclusion (Table 2).

3. Proposed Renoprotective Mechanisms of SGLT2i

3.1. Tubulo-Glomerular Feedback Mechanism (TGF)

It has been well recognized that SGLT2i decrease serum glucose level by increasing urinary glucose excretion [61,62,63]. Renoprotective benefits of SGLT2i, apart from glucose-lowering mechanisms, are also well established. Tubulo-glomerular feedback is, thus far, the most well-explained mechanism. Sodium hydrogen exchanger (NHE3) activity is downregulated in proximal tubule by SGLT2i, reducing sodium reabsorption. This leads to a considerable amount of sodium being delivered to macula-densa, causing afferent arteriolar vasoconstriction and further reducing renal blood flow [47,64]. SGLT2i in synergy with ACE inhibitors contribute to afferent arteriole vasoconstriction and efferent vasodilatation, reducing intra-glomerular pressure [65,66,67,68].

3.2. Non-TGF Mediated Mechanisms

SGLT2i potentiate natriuresis, reduce total body sodium content, and lower blood pressure (EMPA REG Outcomes Trial) [21,69]. They further potentiate reduction of interstitial volume, improve endothelial function and vascular tone [70,71,72]. SGLT2i also contributes to caloric loss with substantial improvement in insulin resistance and hemoglobin A1C. This effect becomes evident within the first few weeks of treatment initiation and is maintained long-term [73,74]. The role of SGLT2i on modulating RAAS is controversial; studies by Yoshimoto et al. reported no significant RAAS activation [75]. Furthermore, SGLT2i also potentiates reduction in albuminuria in diabetic kidney disease by reducing intra-glomerular pressure and podocyte stabilization [20,43,76,77].

3.3. Antioxidant Properties

SGLT2i exhibits antioxidant properties by reducing free radical generation. Phlorizin was initially studied by Osorio et al. and was found to reduce oxidative stress in diabetic rats by its effect on catalase and glutathione peroxidase and decrease in nitrogen-free radicles [78]. Tang et al. further reported that dapagliflozin slowed the progression of diabetic nephropathy by decreasing the production of free radical progenitors, including nicotinamide adenine dinucleotide phosphate oxidase (NOX) 4, and NOX 2 [79]. In studies of murine diabetic heart by Xue et al., empagliflozin reduced oxidative stress through activating NRF2/ARE signaling pathway in type 2 diabetic models [80].

3.4. Anti-Inflammatory Properties

Various inflammatory cytokines are upregulated in hyperglycemic milieu [81,82]. Independent of glucose lowering effects, SGLT2i via caspase-1 pathway inhibits secretion of IL-1beta by macrophages, thereby reducing inflammation and fibrosis [83,84,85]. Empagliflozin studies by Panchapakesan et al. on proximal tubular cells demonstrated decreased expression of Toll-like receptor 2 and 4, and NF-kB, further reducing inflammation and subsequent fibrosis [86]. Recently, SGLT2i has demonstrated reduction in interstitial fibrosis along with protection against ischemia-reperfusion injury by upregulating vascular endothelial growth factor (VEGF)-A in a mice model [87].

3.5. Cortical Hypoxia Reduction

SGLT2i modulate alterations in oxygen consumption and, therefore, are able to reduce renal cortical hypoxia. It has been noticed that decreased activity of Na-K-ATPase and reduced accumulation of intracellular glucose and sodium contribute to decreased oxygen utility. Fibroblasts might recover erythropoietin production as cortical hypoxia improves [76]. Recent studies have also reported inhibition of HIF-1α expression and related target genes (VEGF, GLUT1, etc.) by SGLT2i along with subsequent reduction in interstitial fibrosis in diabetic kidneys [88].

4. Proposed Cardioprotective Mechanisms of SGLT2i

As discussed above, SGLT2i can cause natriuresis, and account for 7% of plasma volume reduction, leading to a decrease in preload [89]. In a meta-analysis, which included 34 randomized controlled studies, SGLT2i increased HDL cholesterol and reduced serum triglycerides [90]. SGLT2i reportedly exhibit significant cardiac benefits similar to renoprotection by lowering body weight, optimizing lipid panel and blood pressure control, improving endothelial function, and reducing arterial stiffness [19]. Apart from described hemodynamic effects, SGLT2i contributes to direct myocardial benefits by promoting lipolysis and ketogenesis [91]. It has been hypothesized that myocardial ketone oxidation could explain the cardioprotective effect of empagliflozin in diabetic patients [92,93]. The proposed mechanism emphasizes utilization of ketone bodies as the preferred heart muscle fuel. Subsequently, this leads to maintenance of mitochondrial integrity and decrease in generation of reactive oxygen species. However, more in vivo studies are needed to determine the exact role of ketone oxidation on cardioprotective effect of empagliflozin.
SGLT2i also inhibits NHE1 in the myocardium and lower intracellular sodium and calcium content leading to reduced pro-oxidant and pro-thrombotic state as reported in empagliflozin experimental models [94]. SGLT2i potentiate natriuresis in heart failure patients by inhibiting NHE3 in proximal tubule [95]. In studies by Garvey et al., canagliflozin led to 25% reduction of serum leptin levels, which manifest pro inflammatory properties and a 17% increase of serum adiponectin, which demonstrates anti-inflammatory properties, as compared to glimepiride [96]. Epicardial fat plays a crucial role in heart failure patients and, reportedly, was reduced by dapagliflozin in experimental models in a study by Sato et al. [97]. Finally, the anti-fibrotic effects of SGLT2i manifest through inhibition of myofibroblast differentiation and reduction in pro-inflammatory cytokines, thereby reducing left ventricle mass and improving ejection fraction [98]. Renoprotective and cardioprotective mechanisms of SGLT2i are illustrated in Figure 1.

5. Conclusions

SGLT2i has revolutionized treatment approach in patients with type 2 diabetes mellitus. Although primarily glucosuric agents, their renoprotective property appears to be independent of its glucose-lowering effects. Even though multiple randomized controlled studies have illustrated beneficial effects of SGLT2i regarding renal outcomes, a certain degree of hesitation still exists in prescribing combination therapy with SGLT2i in insulin naive diabetic patients. Randomized controlled studies to evaluate therapeutic benefits and renal outcomes of combination therapies as initial approach in patients with type 2 diabetes might further guide the process of establishing more organized treatment approach. Additionally, further controlled studies are required in evaluating the potential role of SGLT2i in reducing proteinuria in non-diabetic CKD patients.

Author Contributions

S.R.K., K.K., and W.C. drafted the manuscript. All authors gave comments on the earlier versions of the manuscript and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors deny any conflict of interest.

References

  1. Collins, A.J.; Foley, R.N.; Herzog, C.; Chavers, B.; Gilbertson, D.; Ishani, A.; Kasiske, B.; Liu, J.; Mau, L.W.; McBean, M.; et al. US renal data system 2010 annual data report. Am. J. Kidney Dis. 2011, 57, 526. [Google Scholar] [CrossRef]
  2. Lytvyn, Y.; Bjornstad, P.; van Raalte, D.H.; Heerspink, H.L.; Cherney, D.Z.I. The new biology of diabetic kidney disease—Mechanisms and therapeutic implications. Endocr. Rev. 2019, 41, 202–231. [Google Scholar] [CrossRef] [PubMed]
  3. Kaewput, W.; Thongprayoon, C.; Rangsin, R.; Bathini, T.; Torres-Ortiz, A.; Mao, M.A.; Cheungpasitporn, W. Incidence and risk factors associated with outpatient hypoglycemia in patients with type 2 diabetes and chronic kidney disease: A nationwide study. Endocr. Res. 2020, 1–9. [Google Scholar] [CrossRef] [PubMed]
  4. Kaewput, W.; Thongprayoon, C.; Chewcharat, A.; Rangsin, R.; Satirapoj, B.; Kaewput, C.; Suwannahitatorn, P.; Bathini, T.; Mao, M.A.; Cato, L.D.; et al. Rate of kidney function decline and factors predicting progression of kidney disease in type 2 diabetes mellitus patients with reduced kidney function: A nationwide retrospective cohort study. Ther. Apher.Dial. 2020. [Google Scholar] [CrossRef] [PubMed]
  5. Kaewput, W.; Thongprayoon, C.; Varothai, N.; Sirirungreung, A.; Rangsin, R.; Bathini, T.; Mao, M.A.; Cheungpasitporn, W. Prevalence and associated factors of hospitalization for dysglycemia among elderly type 2 diabetes patients: A nationwide study. World J. Diabetes 2019, 10, 212–223. [Google Scholar] [CrossRef] [PubMed]
  6. Kaewput, W.; Thongprayoon, C.; Rangsin, R.; Ruangkanchanasetr, P.; Mao, M.A.; Cheungpasitporn, W. Associations of renal function with diabetic retinopathy and visual impairment in type 2 diabetes: A multicenter nationwide cross-sectional study. World J. Nephrol. 2019, 8, 33–43. [Google Scholar] [CrossRef]
  7. Kaewput, W.; Thongprayoon, C.; Rangsin, R.; Mao, M.A.; Satirapoj, B.; Cheungpasitporn, W. The association between renal function and neurological diseases in type 2 diabetes: A multicenter nationwide cross-sectional study. Hosp. Pract. 2019, 47, 46–52. [Google Scholar] [CrossRef]
  8. Kaewput, W.; Thongprayoon, C.; Mungthin, M.; Jindarat, S.; Varothai, N.; Suwannahitatorn, P.; Rangsin, R.; Mao, M.A.; Cheungpasitporn, W. Temporal trends in optimal diabetic care and complications of elderly type 2 diabetes patients in Thailand: A nationwide study. J. Evid. Based Med. 2019, 12, 22–28. [Google Scholar] [CrossRef] [Green Version]
  9. Zatz, R.; Meyer, T.W.; Rennke, H.G.; Brenner, B.M. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc. Natl. Acad. Sci. USA 1985, 82, 5963–5967. [Google Scholar] [CrossRef] [Green Version]
  10. Yaribeygi, H.; Atkin, S.L.; Pirro, M.; Sahebkar, A. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. J. Cell. Physiol. 2019, 234, 8286–8294. [Google Scholar] [CrossRef]
  11. Tonneijck, L.; Muskiet, M.H.A.; Smits, M.M.; van Bommel, E.J.; Heerspink, H.J.L.; van Raalte, D.H.; Joles, J.A. Glomerular hyperfiltration in diabetes: Mechanisms, clinical significance, and treatment. J. Am. Soc. Nephrol. JASN 2017, 28, 1023–1039. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Warren, A.M.; Knudsen, S.T.; Cooper, M.E. Diabetic nephropathy: An insight into molecular mechanisms and emerging therapies. Expert Opin. Ther. Targets 2019, 23, 579–591. [Google Scholar] [CrossRef] [PubMed]
  13. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S.; et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001, 345, 861–869. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Tuttle, K.R.; Cherney, D.Z. Sodium glucose cotransporter 2 inhibition heralds a call-to-action for diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 2020, 15, 285–288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. De Azevedo, M.J.; Ramos, O.L.; Gross, J.L. Lack of effect of captopril on glomerular hyperfiltration in normoalbuminuric normotensive insulin-dependent diabetic patients. Horm. Metab. Res. 1997, 29, 516–519. [Google Scholar] [CrossRef]
  16. Dekkers, C.C.J.; Gansevoort, R.T. Sodium-glucose cotransporter 2 inhibitors: Extending the indication to non-diabetic kidney disease? Nephrol. Dial. Transplant. 2020, 35, i33–i42. [Google Scholar] [CrossRef] [Green Version]
  17. Nespoux, J.; Vallon, V. SGLT2 inhibition and kidney protection. Clin. Sci. 2018, 132, 1329–1339. [Google Scholar] [CrossRef]
  18. Thomson, S.C.; Vallon, V. Renal effects of sodium-glucose co-transporter inhibitors. Am. J. Cardiol. 2019, 124, S28–S35. [Google Scholar] [CrossRef] [Green Version]
  19. Tentolouris, A.; Vlachakis, P.; Tzeravini, E.; Eleftheriadou, I.; Tentolouris, N. SGLT2 inhibitors: A review of their antidiabetic and cardioprotective effects. Int. J. Environ. Res. Publ. Health 2019, 16, 2965. [Google Scholar] [CrossRef] [Green Version]
  20. Bae, J.H.; Park, E.G.; Kim, S.; Kim, S.G.; Hahn, S.; Kim, N.H. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Sci. Rep. 2019, 9, 13009. [Google Scholar] [CrossRef] [Green Version]
  21. Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015, 373, 2117–2128. [Google Scholar] [CrossRef] [PubMed]
  22. Wiviott, S.D.; Raz, I.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Silverman, M.G.; Zelniker, T.A.; Kuder, J.F.; Murphy, S.A.; et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2019, 380, 347–357. [Google Scholar] [CrossRef] [PubMed]
  23. Zelniker, T.A.; Wiviott, S.D.; Raz, I.; Im, K.; Goodrich, E.L.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Furtado, R.H.M.; et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019, 393, 31–39. [Google Scholar] [CrossRef]
  24. Arnott, C.; Li, Q.; Kang, A.; Neuen, B.L.; Bompoint, S.; Lam, C.S.P.; Rodgers, A.; Mahaffey, K.W.; Cannon, C.P.; Perkovic, V.; et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. J. Am. Heart Assoc. 2020, 9, e014908. [Google Scholar] [CrossRef] [PubMed]
  25. Makarova, E.; Górnaś, P.; Konrade, I.; Tirzite, D.; Cirule, H.; Gulbe, A.; Pugajeva, I.; Seglina, D.; Dambrova, M. Acute anti-hyperglycaemic effects of an unripe apple preparation containing phlorizin in healthy volunteers: A preliminary study. J. Sci. Food Agric. 2015, 95, 560–568. [Google Scholar] [CrossRef]
  26. Chao, E.C.; Henry, R.R. SGLT2 inhibition-A novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 2010, 9, 551–559. [Google Scholar] [CrossRef]
  27. De Fronzo, R.A.; Norton, L.; Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 2017, 13, 11–26. [Google Scholar] [CrossRef]
  28. Van Baar, M.J.B.; van Ruiten, C.C.; Muskiet, M.H.A.; van Bloemendaal, L.; RG, I.J.; van Raalte, D.H. SGLT2 inhibitors in combination therapy: From mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 2018, 41, 1543–1556. [Google Scholar] [CrossRef] [Green Version]
  29. Heerspink, H.J.; Perkins, B.A.; Fitchett, D.H.; Husain, M.; Cherney, D.Z. sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016, 134, 752–772. [Google Scholar] [CrossRef]
  30. Cherney, D.; Perkins, B.A.; Lytvyn, Y.; Heerspink, H.; Rodríguez-Ortiz, M.E.; Mischak, H. The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. PLoS ONE 2017, 12, e0186910. [Google Scholar] [CrossRef]
  31. Cherney, D.Z.I.; Cooper, M.E.; Tikkanen, I.; Pfarr, E.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Lund, S.S. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018, 93, 231–244. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Hadjadj, S.; Rosenstock, J.; Meinicke, T.; Woerle, H.J.; Broedl, U.C. Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care 2016, 39, 1718–1728. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Henry, R.R.; Murray, A.V.; Marmolejo, M.H.; Hennicken, D.; Ptaszynska, A.; List, J.F. Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int. J. Clin. Pract. 2012, 66, 446–456. [Google Scholar] [CrossRef] [PubMed]
  34. Rosenstock, J.; Chuck, L.; González-Ortiz, M.; Merton, K.; Craig, J.; Capuano, G.; Qiu, R. initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes. Diabetes Care 2016, 39, 353–362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Introduction: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020, 43, S1–S2. [CrossRef] [PubMed] [Green Version]
  36. Milder, T.Y.; Stocker, S.L.; Abdel Shaheed, C.; McGrath-Cadell, L.; Samocha-Bonet, D.; Greenfield, J.R.; Day, R.O. Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: A systematic review and meta-analysis. J. Clin. Med. 2019, 8, 45. [Google Scholar] [CrossRef] [Green Version]
  37. Bersoff-Matcha, S.J.; Chamberlain, C.; Cao, C.; Kortepeter, C.; Chong, W.H. fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. Ann. Intern. Med. 2019, 170, 764–769. [Google Scholar] [CrossRef]
  38. Danne, T.; Garg, S.; Peters, A.L.; Buse, J.B.; Mathieu, C.; Pettus, J.H.; Alexander, C.M.; Battelino, T.; Ampudia-Blasco, F.J.; Bode, B.W.; et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 2019, 42, 1147–1154. [Google Scholar] [CrossRef] [Green Version]
  39. Goldenberg, R.M.; Gilbert, J.D.; Hramiak, I.M.; Woo, V.C.; Zinman, B. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA protocol. Diabetes Obes. Metab. 2019, 21, 2192–2202. [Google Scholar] [CrossRef]
  40. Dave, C.V.; Schneeweiss, S.; Kim, D.; Fralick, M.; Tong, A.; Patorno, E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: A population-based cohort study. Ann. Intern. Med. 2019, 171, 248–256. [Google Scholar] [CrossRef]
  41. Wanner, C.; Inzucchi, S.E.; Lachin, J.M.; Fitchett, D.; von Eynatten, M.; Mattheus, M.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Zinman, B.; et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 2016, 375, 323–334. [Google Scholar] [CrossRef]
  42. Neuen, B.L.; Ohkuma, T.; Neal, B.; Matthews, D.R.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Li, Q.; Jardine, M.; Oh, R.; et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program. J. Am. Soc. Nephrol. 2019, 30, 2229–2242. [Google Scholar] [CrossRef] [PubMed]
  43. Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 2019, 380, 2295–2306. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R.; et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 2017, 377, 644–657. [Google Scholar] [CrossRef] [PubMed]
  45. Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Erondu, N.; Shaw, W.; Barrett, T.D.; Weidner-Wells, M.; Deng, H.; Matthews, D.R.; et al. Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol. 2018, 6, 691–704. [Google Scholar] [CrossRef]
  46. Yale, J.F.; Bakris, G.; Cariou, B.; Nieto, J.; David-Neto, E.; Yue, D.; Wajs, E.; Figueroa, K.; Jiang, J.; Law, G.; et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes. Metab. 2014, 16, 1016–1027. [Google Scholar] [CrossRef] [PubMed]
  47. Kohan, D.E.; Fioretto, P.; Tang, W.; List, J.F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014, 85, 962–971. [Google Scholar] [CrossRef] [Green Version]
  48. Fioretto, P.; del Prato, S.; Buse, J.B.; Goldenberg, R.; Giorgino, F.; Reyner, D.; Langkilde, A.M.; Sjöström, C.D.; Sartipy, P. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes. Metab. 2018, 20, 2532–2540. [Google Scholar] [CrossRef] [Green Version]
  49. Martinez, F.A.; Serenelli, M.; Nicolau, J.C.; Petrie, M.C.; Chiang, C.E.; Tereshchenko, S.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: Insights from DAPA-HF. Circulation 2020, 141, 100–111. [Google Scholar] [CrossRef]
  50. Cherney, D.Z.I.; Dekkers, C.C.J.; Barbour, S.J.; Cattran, D.; Abdul Gafor, A.H.; Greasley, P.J.; Laverman, G.D.; Lim, S.K.; Di Tanna, G.L.; Reich, H.N.; et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020, 8, 582–593. [Google Scholar] [CrossRef]
  51. Häring, H.U.; Merker, L.; Seewaldt-Becker, E.; Weimer, M.; Meinicke, T.; Woerle, H.J.; Broedl, U.C. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013, 36, 3396–3404. [Google Scholar] [CrossRef] [Green Version]
  52. Barnett, A.H.; Mithal, A.; Manassie, J.; Jones, R.; Rattunde, H.; Woerle, H.J.; Broedl, U.C. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014, 2, 369–384. [Google Scholar] [CrossRef]
  53. Halden, T.A.S.; Kvitne, K.E.; Midtvedt, K.; Rajakumar, L.; Robertsen, I.; Brox, J.; Bollerslev, J.; Hartmann, A.; Asberg, A.; Jenssen, T. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019, 42, 1067–1074. [Google Scholar] [CrossRef]
  54. Allegretti, A.S.; Zhang, W.; Zhou, W.; Thurber, T.K.; Rigby, S.P.; Bowman-Stroud, C.; Trescoli, C.; Serusclat, P.; Freeman, M.W.; Halvorsen, Y.C.; et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am. J. Kidney Dis. 2019, 74, 328–337. [Google Scholar] [CrossRef]
  55. Zhang, Y.; Thai, K.; Kepecs, D.M.; Gilbert, R.E. Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS ONE 2016, 11, e0144640. [Google Scholar] [CrossRef] [Green Version]
  56. Cassis, P.; Locatelli, M.; Cerullo, D.; Corna, D.; Buelli, S.; Zanchi, C.; Villa, S.; Morigi, M.; Remuzzi, G.; Benigni, A.; et al. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight 2018, 3. [Google Scholar] [CrossRef] [Green Version]
  57. Ma, Q.; Steiger, S.; Anders, H.J. Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. Physiol. Rep. 2017, 5. [Google Scholar] [CrossRef]
  58. Rajasekeran, H.; Reich, H.N.; Hladunewich, M.A.; Cattran, D.; Lovshin, J.A.; Lytvyn, Y.; Bjornstad, P.; Lai, V.; Tse, J.; Cham, L.; et al. Dapagliflozin in focal segmental glomerulosclerosis: A combined human-rodent pilot study. Am. J. Physiol. Renal. Physiol. 2018, 314, F412–F422. [Google Scholar] [CrossRef] [Green Version]
  59. Bays, H.E.; Weinstein, R.; Law, G.; Canovatchel, W. Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. Obesity 2014, 22, 1042–1049. [Google Scholar] [CrossRef] [Green Version]
  60. Jaikumkao, K.; Pongchaidecha, A.; Chueakula, N.; Thongnak, L.O.; Wanchai, K.; Chatsudthipong, V.; Chattipakorn, N.; Lungkaphin, A. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats. Diabetes Obes. Metab. 2018, 20, 2617–2626. [Google Scholar] [CrossRef]
  61. Yaribeygi, H.; Butler, A.E.; Atkin, S.L.; Katsiki, N.; Sahebkar, A. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. J. Cell Physiol. 2018, 234, 223–230. [Google Scholar] [CrossRef] [Green Version]
  62. Ku, E.J.; Lee, D.H.; Jeon, H.J.; Oh, T.K. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. Diabetes Res. Clin. Pract. 2019, 151, 65–73. [Google Scholar] [CrossRef] [Green Version]
  63. McGurnaghan, S.J.; Brierley, L.; Caparrotta, T.M.; McKeigue, P.M.; Blackbourn, L.A.K.; Wild, S.H.; Leese, G.P.; McCrimmon, R.J.; McKnight, J.A.; Pearson, E.R.; et al. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: A real-world observational study. Diabetologia 2019, 62, 621–632. [Google Scholar] [CrossRef] [Green Version]
  64. Petrykiv, S.; Sjöström, C.D.; Greasley, P.J.; Xu, J.; Persson, F.; Heerspink, H.J.L. differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin. J. Am. Soc. Nephrol. 2017, 12, 751–759. [Google Scholar] [CrossRef] [Green Version]
  65. Chan, G.C.W.; Tang, S.C.W. SGLT2 inhibitor empagliflozin: Finally at the latter stage of understanding? Kidney Int. 2018, 93, 22–24. [Google Scholar] [CrossRef] [Green Version]
  66. Škrtić, M.; Cherney, D.Z. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 2015, 24, 96–103. [Google Scholar] [CrossRef] [PubMed]
  67. Kidokoro, K.; Cherney, D.Z.I.; Bozovic, A.; Nagasu, H.; Satoh, M.; Kanda, E.; Sasaki, T.; Kashihara, N. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation 2019, 140, 303–315. [Google Scholar] [CrossRef]
  68. Eickhoff, M.K.; Dekkers, C.C.J.; Kramers, B.J.; Laverman, G.D.; Frimodt-Møller, M.; Jørgensen, N.R.; Faber, J.; Danser, A.H.J.; Gansevoort, R.T.; Rossing, P.; et al. Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. J. Clin. Med. 2019, 8, 779. [Google Scholar] [CrossRef] [Green Version]
  69. Karg, M.V.; Bosch, A.; Kannenkeril, D.; Striepe, K.; Ott, C.; Schneider, M.P.; Boemke-Zelch, F.; Linz, P.; Nagel, A.M.; Titze, J.; et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: A randomised controlled trial. Cardiovasc. Diabetol. 2018, 17, 5. [Google Scholar] [CrossRef] [Green Version]
  70. Aroor, A.R.; Das, N.A.; Carpenter, A.J.; Habibi, J.; Jia, G.; Ramirez-Perez, F.I.; Martinez-Lemus, L.; Manrique-Acevedo, C.M.; Hayden, M.R.; Duta, C.; et al. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc. Diabetol. 2018, 17, 108. [Google Scholar] [CrossRef]
  71. Lee, D.M.; Battson, M.L.; Jarrell, D.K.; Hou, S.; Ecton, K.E.; Weir, T.L.; Gentile, C.L. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc. Diabetol. 2018, 17, 62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Weber, M.A.; Mansfield, T.A.; Alessi, F.; Iqbal, N.; Parikh, S.; Ptaszynska, A. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press 2016, 25, 93–103. [Google Scholar] [CrossRef]
  73. Rajeev, S.P.; Cuthbertson, D.J.; Wilding, J.P.H. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes. Metabol. 2016, 18, 125–134. [Google Scholar] [CrossRef] [PubMed]
  74. Alicic, R.Z.; Johnson, E.J.; Tuttle, K.R. SGLT2 Inhibition for the prevention and treatment of diabetic kidney disease: A review. Am. J. Kidney Dis. 2018, 72, 267–277. [Google Scholar] [CrossRef] [PubMed]
  75. Yoshimoto, T.; Furuki, T.; Kobori, H.; Miyakawa, M.; Imachi, H.; Murao, K.; Nishiyama, A. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J. Investig. Med. 2017, 65, 1057–1061. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Cherney, D.Z.; Perkins, B.A.; Soleymanlou, N.; Maione, M.; Lai, V.; Lee, A.; Fagan, N.M.; Woerle, H.J.; Johansen, O.E.; Broedl, U.C.; et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014, 129, 587–597. [Google Scholar] [CrossRef] [Green Version]
  77. Takashima, H.; Yoshida, Y.; Nagura, C.; Furukawa, T.; Tei, R.; Maruyama, T.; Maruyama, N.; Abe, M. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. Diab. Vasc. Dis. Res. 2018, 15, 469–472. [Google Scholar] [CrossRef] [Green Version]
  78. Osorio, H.; Coronel, I.; Arellano, A.; Pacheco, U.; Bautista, R.; Franco, M.; Escalante, B. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid. Med. Cell. Longev. 2012, 2012, 542042. [Google Scholar] [CrossRef] [Green Version]
  79. Tang, L.; Wu, Y.; Tian, M.; Sjöström, C.D.; Johansson, U.; Peng, X.-R.; Smith, D.M.; Huang, Y. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am. J. Physiol. Endocrinol. Metabol. 2017, 313, E563–E576. [Google Scholar] [CrossRef]
  80. Li, C.; Zhang, J.; Xue, M.; Li, X.; Han, F.; Liu, X.; Xu, L.; Lu, Y.; Cheng, Y.; Li, T.; et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc. Diabetol. 2019, 18, 15. [Google Scholar] [CrossRef]
  81. Boels, M.G.S.; Koudijs, A.; Avramut, M.C.; Sol, W.; Wang, G.; van Oeveren-Rietdijk, A.M.; van Zonneveld, A.J.; de Boer, H.C.; van der Vlag, J.; van Kooten, C.; et al. Systemic monocyte chemotactic protein-1 inhibition modifies renal macrophages and restores glomerular endothelial glycocalyx and barrier function in diabetic nephropathy. Am. J. Pathol. 2017, 187, 2430–2440. [Google Scholar] [CrossRef] [Green Version]
  82. Vallon, V.; Gerasimova, M.; Rose, M.A.; Masuda, T.; Satriano, J.; Mayoux, E.; Koepsell, H.; Thomson, S.C.; Rieg, T. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am. J. Physiol. Renal. Physiol. 2014, 306, F194–F204. [Google Scholar] [CrossRef] [Green Version]
  83. Heerspink, H.J.L.; Perco, P.; Mulder, S.; Leierer, J.; Hansen, M.K.; Heinzel, A.; Mayer, G. Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 2019, 62, 1154–1166. [Google Scholar] [CrossRef] [Green Version]
  84. Dekkers, C.C.J.; Petrykiv, S.; Laverman, G.D.; Cherney, D.Z.; Gansevoort, R.T.; Heerspink, H.J.L. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes. Metab. 2018, 20, 1988–1993. [Google Scholar] [CrossRef] [Green Version]
  85. Leng, W.; Ouyang, X.; Lei, X.; Wu, M.; Chen, L.; Wu, Q.; Deng, W.; Liang, Z. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(-/-) mice. Mediat. Inflamm. 2016, 2016, 6305735. [Google Scholar] [CrossRef] [Green Version]
  86. Panchapakesan, U.; Pegg, K.; Gross, S.; Komala, M.G.; Mudaliar, H.; Forbes, J.; Pollock, C.; Mather, A. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS ONE 2013, 8, e54442. [Google Scholar] [CrossRef] [Green Version]
  87. Zhang, Y.; Nakano, D.; Guan, Y.; Hitomi, H.; Uemura, A.; Masaki, T.; Kobara, H.; Sugaya, T.; Nishiyama, A. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor–dependent pathway after renal injury in mice. Kidney Int. 2018, 94, 524–535. [Google Scholar] [CrossRef] [Green Version]
  88. Bessho, R.; Takiyama, Y.; Takiyama, T.; Kitsunai, H.; Takeda, Y.; Sakagami, H.; Ota, T. Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci. Rep. 2019, 9, 14754. [Google Scholar] [CrossRef] [Green Version]
  89. Lambers Heerspink, H.J.; de Zeeuw, D.; Wie, L.; Leslie, B.; List, J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metabol. 2013, 15, 853–862. [Google Scholar] [CrossRef] [Green Version]
  90. Storgaard, H.; Gluud, L.L.; Bennett, C.; Grøndahl, M.F.; Christensen, M.B.; Knop, F.K.; Vilsbøll, T. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS ONE 2016, 11, e0166125. [Google Scholar] [CrossRef]
  91. Ogawa, W.; Sakaguchi, K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors. J. Diabetes Investig. 2016, 7, 135–138. [Google Scholar] [CrossRef] [PubMed]
  92. Shimazu, T.; Hirschey, M.D.; Newman, J.; He, W.; Shirakawa, K.; Le Moan, N.; Grueter, C.A.; Lim, H.; Saunders, L.R.; Stevens, R.D.; et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013, 339, 211–214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Lopaschuk, G.D.; Verma, S. Empagliflozin’s fuel hypothesis: Not so soon. Cell Metabolism. 2016, 24, 200–202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Baartscheer, A.; Schumacher, C.A.; Wüst, R.C.I.; Fiolet, J.W.T.; Stienen, G.J.M.; Coronel, R.; Zuurbier, C.J. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 2017, 60, 568–573. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Gallo, L.A.; Wright, E.M.; Vallon, V. Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. Diabetes Vasc. Disease Res. 2015, 12, 78–89. [Google Scholar] [CrossRef] [Green Version]
  96. Garvey, W.T.; van Gaal, L.; Leiter, L.A.; Vijapurkar, U.; List, J.; Cuddihy, R.; Ren, J.; Davies, M.J. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism 2018, 85, 32–37. [Google Scholar] [CrossRef] [Green Version]
  97. Sato, T.; Aizawa, Y.; Yuasa, S.; Kishi, S.; Fuse, K.; Fujita, S.; Ikeda, Y.; Kitazawa, H.; Takahashi, M.; Sato, M.; et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc. Diabetol. 2018, 17, 6. [Google Scholar] [CrossRef] [Green Version]
  98. Lee, T.M.; Chang, N.C.; Lin, S.Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med. 2017, 104, 298–310. [Google Scholar] [CrossRef]
Jcm 09 02723 g001 550
Figure 1. Renoprotective and cardioprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors. R = renoprotective; C–predominantly cardioprotective; R + C- renoprotective and cardioprotective; Jcm 09 02723 i001 - decreased.
Figure 1. Renoprotective and cardioprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors. R = renoprotective; C–predominantly cardioprotective; R + C- renoprotective and cardioprotective; Jcm 09 02723 i001 - decreased.
Jcm 09 02723 g001
Table
Table 1. Randomized placebo-controlled trials demonstrating the treatment outcomes of SGLT2 inhibitors vs. placebo in type 2 diabetes mellitus with CKD.
Table 1. Randomized placebo-controlled trials demonstrating the treatment outcomes of SGLT2 inhibitors vs. placebo in type 2 diabetes mellitus with CKD.
Clinical TrialYearTrial RegistrationTotal Sample SizeCKD PatientsKidney Function Inclusion CriteriaFollow-UpReported Renal Outcomes
Canagliflozin
CANVAS and
CANVAS-R [44,45]		2017
2018		NCT01032629
NCT01989754		101422039eGFR ≥ 30188 wks↓ sustained loss of kidney function, eGFR decline, albuminuria, the need for RRT, and death from renal causes
DIA3004 [46]2014NCT01064414269269eGFR ≥ 30 and < 5052 wks↓ eGFR decline and albuminuria
CREDENCE [43]2019NCT0206579144012181eGFR ≥ 302.6 yrs↓ Renal composite outcomes (ESKD, doubling in SCr, renal or CV death) in both primary and secondary prevention group
The trial stopped early due to overwhelming efficacy
Dapagliflozin
MB102029 [47]2014NCT00663260252252eGFR ≥ 30 and < 60104 wks↓ eGFR decline, albuminuria, and hyperkalemia
Slight drop in eGFR during drug initiation
DERIVE [48]2018NCT02413398321321eGFR ≥ 45 and < 6024 wks↓ Renal related adverse events
Slight drop in eGFR during drug initiation
DECLARE-TIMI 58 [22]2018NCT01730534171601265CrCl ≥ 60 mL/min4.2 yrs↓ Renal composite outcomes
↓ Acute kidney injury
DAPA-HF [49]2020NCT030361244724N/AeGFR ≥ 303 yrs↓ Doubling in SCr
DIAMOND [50]2020NCT031906945333eGFR ≥ 256 wksNo effect on proteinuria reduction in CKD without diabetes
Reversible decline in eGFR noted
Empagliflozin
EMPA-REG OUTCOME [21]2015NCT0113167670201819eGFR ≥ 303.1 yrs↓ eGFR decline, and renal composite outcomes
EMPA-REG METSU [51]2013NCT0115960066658eGFR ≥ 3024 wks↓ Renal composite outcomes
EMPA-REG RENAL [52]2014NCT01164501738448eGFR ≥ 1552 wks↓ Renal composite outcomes
Halden, et al. [53]2019NCT031574144444 (KTx)eGFR ≥ 3024 wks↓ eGFR within 8 weeks of treatment
No change in eGFR from 8-24 weeks
Bexagliflozin
Allegretti, et al. [54]2019NCT02836873312312eGFR ≥ 30 and < 6024 wks↓ albuminuria
Study not designed to evaluate the impact on long-term kidney disease
Abbreviations: SGLT2-sodium-glucose co-transporter 2; CKD—chronic kidney disease; CrCl—creatinine clearance; CV—cardiovascular; eGFR—estimated glomerular filtration rate; ESKD—end-stage kidney disease; KTx—kidney transplant; RRT—renal replacement therapy; SCr—serum creatinine.
Table
Table 2. Trials demonstrating the treatment outcomes of SGLT2 inhibitor in non-diabetics with chronic kidney disease.
Table 2. Trials demonstrating the treatment outcomes of SGLT2 inhibitor in non-diabetics with chronic kidney disease.
Clinical TrialYearTrial TypeTotal Sample SizeKidney Function Inclusion CriteriaFollow-UpReported Renal Outcomes
Dapagliflozin
Zhang et al. [55]2016Pre-clinical53Subtotal Nephrectomized rats.12 weeksNo improvement in proteinuria, tubulointerstitial fibrosis or eGFR.
Cassis et al. [56]2018Pre-clinical37Non-diabetic proteinuric mice, unilateral nephrectomy.23 daysDecrease in podocyte damage, reduction in proteinuria
Jaikumkao et al. [60]2018Pre-clinical24Obese prediabetic rats4 weeksDecrease in podocyte damage, reduction in proteinuria
Rajasekeran et al. [58]2018Clinical10Biopsy proven FSGS, eGFR > 45mL/min, proteinuria 30 mg-6 gr5 weeksNo effect on bodyweight, eGFR or proteinuria
DIAMOND [50]2020Clinical53eGFR ≥ 256 weeksNo effect on proteinuria reduction in CKD without diabetes
Reversible decline in eGFR noted
Empagliflozin
Ma et al. [57]2017Pre-clinical20CKD mice7–14 daysNo reno-protective benefit
Canagliflozin
Bays et al. [59]2014Clinical376Non-diabetic obese patients, BMI 30-5012 weeksNo renal benefit
Abbreviations: SGLT2-sodium-glucose co-transporter 2; CKD—chronic kidney disease; eGFR—estimated glomerular filtration rate; FSGS—focal segmental glomerulosclerosis; BMI—body mass index.

Share and Cite

MDPI and ACS Style

Kanduri, S.R.; Kovvuru, K.; Hansrivijit, P.; Thongprayoon, C.; Vallabhajosyula, S.; Pivovarova, A.I.; Chewcharat, A.; Garla, V.; Medaura, J.; Cheungpasitporn, W. SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease. J. Clin. Med. 2020, 9, 2723. https://doi.org/10.3390/jcm9092723

AMA Style

Kanduri SR, Kovvuru K, Hansrivijit P, Thongprayoon C, Vallabhajosyula S, Pivovarova AI, Chewcharat A, Garla V, Medaura J, Cheungpasitporn W. SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease. Journal of Clinical Medicine. 2020; 9(9):2723. https://doi.org/10.3390/jcm9092723

Chicago/Turabian Style

Kanduri, Swetha R., Karthik Kovvuru, Panupong Hansrivijit, Charat Thongprayoon, Saraschandra Vallabhajosyula, Aleksandra I. Pivovarova, Api Chewcharat, Vishnu Garla, Juan Medaura, and Wisit Cheungpasitporn. 2020. "SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease" Journal of Clinical Medicine 9, no. 9: 2723. https://doi.org/10.3390/jcm9092723

APA Style

Kanduri, S. R., Kovvuru, K., Hansrivijit, P., Thongprayoon, C., Vallabhajosyula, S., Pivovarova, A. I., Chewcharat, A., Garla, V., Medaura, J., & Cheungpasitporn, W. (2020). SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease. Journal of Clinical Medicine, 9(9), 2723. https://doi.org/10.3390/jcm9092723

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop